BackApimeds Pharmaceuticals US Overview

Apimeds Pharmaceuticals US Total Assets

Track Apimeds Pharmaceuticals US's total assets ($130M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$127.62M
↑ 1110.08% YoYΔ $117.08M vs prior year quarter

Peer trimmed avg / median

Loading

Apimeds Pharmaceuticals US Total Assets History

Loading

Apimeds Pharmaceuticals US vs. peers: Total Assets Comparison

Loading

Apimeds Pharmaceuticals US Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Apimeds Pharmaceuticals US (APUS) FAQ

Apimeds Pharmaceuticals US (APUS) currently reports a total assets of $130M as of June 2026. That compares with $11M in the prior-year period — up 1110.1% year over year. Use the charts on this page to explore Apimeds Pharmaceuticals US's total assets history and peer comparisons.

Apimeds Pharmaceuticals US's total assets increased from $11M to $130M — a 1110.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apimeds Pharmaceuticals US reported $130M in total assets as of June 2026. That compares with $11M in the prior-year period — up 1110.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.